Table 3.
Comparative analysis of AMR profile of ESBL producers and non-producers
| Antimicrobial drugs | Non-ESBL producing UPEC isolates (n = 46) | ESBL producing UPEC isolates (n = 43) | p value | ||
|---|---|---|---|---|---|
| Resistant | Susceptible | Resistant | Susceptible | ||
| Meropenem | 29 (63%) | 17 (37%) | 11 (26%) | 32 (74%) | 0.0006*** |
| Fosfomycin | 0 (0%) | 46 (100%) | 1 (2%) | 42 (98%) | 0.4831 |
| Tobramycin | 17 (37%) | 29 (63%) | 13 (30%) | 30 (70%) | 0.6540 |
| Gentamycin | 7 (15%) | 39 (85%) | 9 (21%) | 34 (79%) | 0.5845 |
| Erythromycin | 45 (98%) | 1 (2%) | 43 (100%) | 0 | 1.0000 |
| Pipemidic Acid | 17 (37%) | 29 (63%) | 23 (54%) | 20 (46%) | 0.5845 |
| Moxifloxacin | 25 (54%) | 21 (46%) | 22 (51%) | 21 (49%) | 0.8332 |
| Ofloxacin | 25 (54%) | 21 (46%) | 16 (37%) | 27 (63%) | 0.1372 |
| Nitrofurantoin | 7 (15%) | 39 (85%) | 1 (2%) | 42 (98%) | 0.0593 |
| Aztreonam | 27 (59%) | 19 (41%) | 34 (79%) | 9 (21%) | 0.0435* |
| Trimethoprim | 33 (72%) | 13 (28%) | 28 (65%) | 15 (35%) | 0.6483 |
| Ceftazidime | 28 (61%) | 18 (39%) | 32 (74%) | 11 (26%) | 0.1847 |
| Ceftriaxone | 33 (72%) | 13 (28%) | 34 (79%) | 9 (21%) | 0.4689 |
| Cefexime | 34 (74%) | 12 (26%) | 34 (79%) | 9 (21%) | 0.6237 |
| Cefotaxime | 35 (76%) | 11 (24%) | 38 (88%) | 5 (12%) | 0.1709 |
| Sulbactam/ cefoperazone | 7 (15%) | 39 (85%) | 9 (21%) | 34 (79%) | 0.5845 |
| Piperacillin/ Tazobactam | 9 (20%) | 37 (80%) | 6 (13%) | 37 (87%) | 0.5763 |
| Amoxycillin | 44 (96%) | 2 (4%) | 40 (93%) | 3 (7%) | 0.6698 |
|
Ampicillin/ sulbactam |
11 (24%) | 35 (76%) | 10 (23%) | 33 (77%) | 1.0000 |
| Amoxicillin / Clavulanic acid | 9 (20%) | 37 (80%) | 7 (17%) | 36 (83%) | 0.7856 |
| Colistin sulphate | 36 (78%) | 10 (22%) | 31 (72%) | 12 (28%) | 0.6242 |
***Indicates extremely statistically significant
*Designates statistically significant